Assessment of the Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) scleral lens on visual acuity for corneal irregularity and ocular surface disease

Parra, Andres S.; Roth, Bryan M.; Nguyen, Taylor M.; Wang, Li; Pflugfelder, Stephen C.; Al-Mohtaseb, Zaina

doi:10.1016/j.jtos.2018.01.003

Cited by 27 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the full cornea-covering and rigid design of the scleral lens, the tear reservoir between the ocular surface and the scleral lens provides prolonged tear lubrication to improve dry eye and help even out the ocular surface subsequently reducing optical aberrations and improving vision 2,13,16,19 . Long-term use of PROSE has been reported to improve visual acuity by 0.20-0.46 logMAR and to successfully sustain vision for several ocular surface diseases and irregular corneas 20 . Heur et al reported the PROSE treatment to be a viable option for SJS patients when conventional treatments have failed 7 .…”

Section: Discussionmentioning

confidence: 99%

“…Schornack reported that Jupiter scleral lenses help buy time for some patients with limbal stem cell deficiency until aggressive surgical measures are inevitable 21 . Despite the variety of commercially available scleral lenses today, most studies have focused on using PROSE and Jupiter Lens [5][6][7][20][21][22][23][24] . There have been only a few studies regarding other scleral lenses 4,6,8,25 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Large diameter scleral lens benefits for Asians with intractable ocular surface diseases: a prospective, single-arm clinical trial

Moon

Lee

Hyon

et al. 2021

Sci Rep

View full text Add to dashboard Cite

To report the efficacy and safety of large diameter scleral lenses and determine their suitability in Asian subjects with intractable ocular surface diseases. This prospective study enrolled intractable ocular surface diseases subjects with uncorrected visual acuity > counting finger but ≥ 0.3 logMAR and best-corrected visual acuity (BCVA) ≥ 0.3 logMAR, to fit large diameter scleral lenses for 12 weeks. 21 eyes (13 subjects) consisting ten eyes (47.6%) with persistent epithelial defects, 6 (28.6%) with graft-versus-host disease, 4 (19.0%) with Stevens–Johnson syndrome and one (4.8%) with severe dry eye were ultimately enrolled. Primary outcome measures were the visual acuity, corneal and conjunctival fluorescein staining, Ocular Surface Disease Index (OSDI), and National Eye Institute 25-Item Visual Function Questionnaire (NEI-VFQ-25). At week 12 with large diameter scleral lenses, BCVA improved from 0.77 logMAR to 0.27 logMAR (P < 0.001). High-grade corneal and conjunctival fluorescein staining proportion decreased from 61.90 to 14.29% and 52.38 to 9.52%, respectively (P = 0.0036 and 0.0063, respectively). OSDI and NEI-VFQ-25 improved from 67.89 to 34.69 and 51.40 to 64.48, respectively (P < 0.001). No adverse effects were observed. In Asians with intractable ocular surface diseases, large diameter scleral lens improves visual acuity and alleviates signs and symptoms of ocular surface diseases without any significant complications.Trial registration Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (Project No. HI12C0015 (A120018)). Clinical Trials.gov, NCT04535388. Registered 18 August 2020—Retrospectively registered, http://clinicaltrials.gov/ct2/show/NCT04535388.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Large diameter scleral lens benefits for Asians with intractable ocular surface diseases: a prospective, single-arm clinical trial

Moon

Lee

Hyon

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…More recently, semi-scleral contact lenses provide excellent visual acuity and comfort in patients with such irregular corneas [441, 463]. Moreover, PROSE scleral lens treatment had a positive impact on visual acuity for a wide range of corneal irregularities, suggesting that PROSE lenses, and perhaps any scleral lens, may offer improvements in visual acuity without surgical intervention [464]. However, patients with lower endothelial cell counts or with Fuchs' dystrophy were more likely to fail treatment with PROSE [245].…”

Section: Irregular Astigmatism From Infection Trauma Dystrophy or Degenerationmentioning

confidence: 99%

“…The same centre found that miniscleral lenses can reduce persistent optical symptoms in patients with good uncorrected acuity after corneal refractive surgery by reducing post-operative spherical aberration [547]. Full scleral lenses, including the custom PROSE [464,519] and the EyePrint Pro [284], have also been effective to treat post-refractive surgery complications including ectasia, optical aberrations, dry eye and neuralgia.…”

Section: Lasik / Prkmentioning

confidence: 99%

BCLA CLEAR – Medical use of contact lenses

Jacobs

Carrasquillo²,

Cottrell

et al. 2021

Contact Lens and Anterior Eye

View full text Add to dashboard Cite

The medical use of contact lenses is a solution for many complex ocular conditions, including high refractive error, irregular astigmatism, primary and secondary corneal ectasia, disfiguring disease, and ocular surface disease. The development of highly oxygen permeable soft and rigid materials has extended the suitability of contact lenses for such applications. There is consistent evidence that bandage soft contact lenses, particularly silicone hydrogel lenses, improve epithelial healing and reduce pain in persistent epithelial defects, after trauma or surgery, and in corneal dystrophies. Drug delivery applications of contact lens hold promise for improving topical therapy. Modern scleral lens practice has achieved great success for both visual rehabilitation and therapeutic applications, including those requiring retention of a tear reservoir or protection from an adverse environment. This report offers a practical and relevant summary of the current evidence for the medical use of contact lenses for all eye care professionals including optometrists, ophthalmologists, opticians, and orthoptists. Topics covered include indications for use in both acute and chronic conditions, lens selection, patient selection, wear and care regimens, and recommended aftercare schedules. Prevention, presentation, and management of complications of medical use are reviewed.

show abstract

“…PROSE treatment has been used in the management of distorted cornea as well as complex ocular surface diseases such as Stevens-Johnson Syndrome (SJS) and ocular graft-versus-host disease (GVHD), with long-term benefits. 5–13…”

Section: Introductionmentioning

confidence: 99%

Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization

Yin

Jacobs

2019

The Ocular Surface

View full text Add to dashboard Cite

Purpose: To report the long-term outcome of Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) for delivery of bevacizumab in the treatment of corneal neovascularization (KNV). Methods: Retrospective, non-comparative, interventional case series of 13 sequential patients treated for KNV at the BostonSight between 2006 and 2017. In all cases, PROSE treatment was initiated for management of ocular surface disease and patients wore PROSE consistently on a daily wear basis prior to bevacizumab treatment. Patients applied a drop of 1% preservative free bevacizumab to the reservoir of PROSE device twice daily. Patients continued with daily wear of the device during treatment and afterwards. Results: 13 patients (8 female and mean age of 45 years) are included with a mean follow-up of 5.1 years (range 6 months to 11 years). Underlying ocular diagnoses included Stevens- Johnson syndrome (7), ocular chronic graft-versus-host disease (2), corneal transplant (2), contact lens-related corneal ulcer and limbal stem cell deficiency (1), and familial dysautonomia (1). Median duration of bevacizumab use was 6 months (range 3 months to 10 years). Twelve cases (92%) had regression of KNV and 10 cases (77%) had improved best-corrected visual acuity (BCVA) with treatment. Median BCVA improved from −1.1 (LogMAR) at baseline, to −0.66 at end of bevacizumab treatment, and remained −0.63 at last follow-up (P=0.047). KNV progressed in one eye after discontinuation of bevacizumab. There were no ophthalmic or systemic complications. Conclusions: Topical bevacizumab used in PROSE is effective in treating KNV and improving vision. Long-term follow-up reveals durable response and no complications.

show abstract

Assessment of the Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) scleral lens on visual acuity for corneal irregularity and ocular surface disease

Cited by 27 publications

References 26 publications

Large diameter scleral lens benefits for Asians with intractable ocular surface diseases: a prospective, single-arm clinical trial

Large diameter scleral lens benefits for Asians with intractable ocular surface diseases: a prospective, single-arm clinical trial

BCLA CLEAR – Medical use of contact lenses

Long-term outcome of using Prosthetic Replacement of Ocular Surface Ecosystem (PROSE) as a drug delivery system for bevacizumab in the treatment of corneal neovascularization

Contact Info

Product

Resources

About